DE68914515D1 - 4-Amino-chinoline und Naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel. - Google Patents

4-Amino-chinoline und Naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.

Info

Publication number
DE68914515D1
DE68914515D1 DE68914515T DE68914515T DE68914515D1 DE 68914515 D1 DE68914515 D1 DE 68914515D1 DE 68914515 T DE68914515 T DE 68914515T DE 68914515 T DE68914515 T DE 68914515T DE 68914515 D1 DE68914515 D1 DE 68914515D1
Authority
DE
Germany
Prior art keywords
naphthyridines
quinolines
medicines
amino
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68914515T
Other languages
English (en)
Other versions
DE68914515T2 (de
Inventor
Etienne Mendes
Jean-Claude Vernieres
Peter Eugene Keane
Andre Bachy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Elf Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8807498A external-priority patent/FR2632305B1/fr
Priority claimed from FR8808025A external-priority patent/FR2632861B1/fr
Application filed by Elf Sanofi SA filed Critical Elf Sanofi SA
Publication of DE68914515D1 publication Critical patent/DE68914515D1/de
Application granted granted Critical
Publication of DE68914515T2 publication Critical patent/DE68914515T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE68914515T 1988-06-06 1989-06-05 4-Amino-chinoline und Naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel. Expired - Fee Related DE68914515T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8807498A FR2632305B1 (fr) 1988-06-06 1988-06-06 Amino-4 aroyl-3 quinoleines et naphtyridines, leur procede de preparation et leur application en therapeutique
FR8808025A FR2632861B1 (fr) 1988-06-15 1988-06-15 Derives d'amino-4 carboxy-3 quinoleines et naphtyridines, leur procede de preparation et leur application comme medicaments

Publications (2)

Publication Number Publication Date
DE68914515D1 true DE68914515D1 (de) 1994-05-19
DE68914515T2 DE68914515T2 (de) 1994-08-18

Family

ID=26226703

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68914515T Expired - Fee Related DE68914515T2 (de) 1988-06-06 1989-06-05 4-Amino-chinoline und Naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.

Country Status (12)

Country Link
US (1) US5026711A (de)
EP (1) EP0346208B1 (de)
JP (1) JP2766672B2 (de)
KR (1) KR910000731A (de)
AU (1) AU624825B2 (de)
CA (1) CA1337073C (de)
DE (1) DE68914515T2 (de)
DK (1) DK273689A (de)
ES (1) ES2063153T3 (de)
IE (1) IE63429B1 (de)
NZ (1) NZ229413A (de)
PT (1) PT90748B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014677A1 (fr) * 1990-03-28 1991-10-03 Otsuka Pharmaceutical Co., Ltd. Derive de quinoline, medicament anti-ulcereux contenant ce derive et production de ce derive
US5395399A (en) * 1993-06-14 1995-03-07 Sport Wrapz, Inc. Thermal wrap for a body member
DE4405712A1 (de) * 1994-02-23 1995-08-24 Basf Ag Substituierte Naphthyridine und deren Verwendung
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
KR0169813B1 (ko) * 1995-07-12 1999-01-15 김종인 4-아미노-3-아실나프티리딘 유도체
WO1998049900A1 (en) * 1997-05-07 1998-11-12 Emory University Haloisoquinoline carboxamide
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2778564B1 (fr) * 1998-05-13 2001-07-13 Sanofi Sa Utilisation de composes reduisant l'apoptose
ATE333281T1 (de) 1998-12-18 2006-08-15 Scios Inc Agonisten und antagonisten von benzodiazepinrezeptoren des peripheren typs
WO2000037085A1 (en) 1998-12-18 2000-06-29 Scios Inc. Treatment of diseases involving cyst formation
DE19960924C2 (de) * 1999-12-17 2002-08-01 Therapeutics Gmbh G.O.T. Amphiphile Polyamine, deren Anwendungen
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
FR2862301B1 (fr) * 2003-11-17 2007-12-21 Aventis Pharma Sa Nouveau procede de preparation de quinoleines 3-fluorees
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
DK1773816T3 (en) 2004-06-24 2015-01-26 Vertex Pharma Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
TW200948803A (en) * 2008-05-07 2009-12-01 Astrazeneca Ab Chemical compounds
US8415333B2 (en) 2009-02-24 2013-04-09 Respiratorious Ab Bronchodilating diazaheteroaryls
NZ624460A (en) 2009-03-20 2015-12-24 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
TWI623537B (zh) * 2012-01-19 2018-05-11 腫瘤療法 科學股份有限公司 １,５-萘啶衍生物與含此之ｍｅｌｋ抑制劑
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) * 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
FR2581382B1 (fr) * 1985-05-06 1987-06-26 Sanofi Sa Derives n-(quinolyl) glycinamides, leur procede de preparation et leur application therapeutique en tant que psychotropes
GB8610981D0 (en) * 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
AU634561B2 (en) * 1989-07-27 1993-02-25 Eli Lilly And Company Naphthyridine derivatives

Also Published As

Publication number Publication date
PT90748B (pt) 1994-10-31
AU3603589A (en) 1989-12-07
JPH0232058A (ja) 1990-02-01
JP2766672B2 (ja) 1998-06-18
IE63429B1 (en) 1995-04-19
CA1337073C (en) 1995-09-19
DK273689A (da) 1989-12-07
NZ229413A (en) 1990-11-27
DK273689D0 (da) 1989-06-02
EP0346208B1 (de) 1994-04-13
DE68914515T2 (de) 1994-08-18
ES2063153T3 (es) 1995-01-01
IE891797L (en) 1989-12-06
AU624825B2 (en) 1992-06-25
KR910000731A (ko) 1991-01-30
EP0346208A1 (de) 1989-12-13
PT90748A (pt) 1989-12-29
US5026711A (en) 1991-06-25

Similar Documents

Publication Publication Date Title
DE68914515D1 (de) 4-Amino-chinoline und Naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE58904567D1 (de) Quinuclidine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung.
DE69016125D1 (de) Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel.
DE69017479D1 (de) Azabicycloheptenderivate und ihre Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende Zubereitungen.
DE69210067D1 (de) Hydraxamsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE58908176D1 (de) Chinacridon-Pigmente, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE19475025I2 (de) Dialkoxypyridine, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende Arzneimittel.
DE3860503D1 (de) 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung.
ATE84040T1 (de) Phenol-substituierte gem-diphosphonat-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
DE3750913D1 (de) Karbostyrilderivate, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung.
DE3771376D1 (de) Indol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3671451D1 (de) 4h-triazolo (4,3-a)(1,4) benzodiazepine, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
ATE40826T1 (de) 4'-demethyl-4-epipodophyllotoxinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
PT85302A (de) 7-acyloxy-6-aminoacyloxypolyxylabdane verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE60767T1 (de) Aminoacyllabdane, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel.
DE3767789D1 (de) Substituierte aminodihydrooxazole, -thiazole und -imidazole, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DE3766299D1 (de) 4-chinolon-3-carbonsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3781627D1 (de) Indanderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, diese enthaltende pharmazeutische zusammensetzungen und erhaltene zwischenprodukte.
DE3888018D1 (de) Substituierte Vinylcephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE3889637D1 (de) Monoazopigmente, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE59006542D1 (de) 2,3-substituierte 1,8-Naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Antidots.
DE58908507D1 (de) Neue 10-Ring-Lactone, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE68912944D1 (de) Phenylpyrole, verwendbar als arzneimittel, verfahren zu ihrer herstellung und ihre verwendung.
DE3674521D1 (de) 6-phenoxymethyl-4-hydroxytetrahydropyran-2-one, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte.
DE3670638D1 (de) Indol-3-yl-chinazolin-1,4-benzodiazepin-5,13-dione, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8339 Ceased/non-payment of the annual fee